Table of Contents

company-logo

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Cabaletta Bio Dividend Announcement

• Cabaletta Bio does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Cabaletta Bio dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Cabaletta Bio Dividend History

Cabaletta Bio Dividend Yield

Cabaletta Bio current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Cabaletta Bio stock? Use our calculator to estimate your expected dividend yield:

Cabaletta Bio Financial Ratios

P/E ratio-1.08
PEG ratio0.01
P/B ratio0.64
ROE-50.10%
Payout ratio0.00%
Current ratio8.11
Quick ratio8.11
Cash Ratio7.46

Cabaletta Bio Dividend FAQ

Does Cabaletta Bio stock pay dividends?
Cabaletta Bio does not currently pay dividends to its shareholders.
Has Cabaletta Bio ever paid a dividend?
No, Cabaletta Bio has no a history of paying dividends to its shareholders. Cabaletta Bio is not known for its dividend payments.
Why doesn't Cabaletta Bio pay dividends?
There are several potential reasons why Cabaletta Bio would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Cabaletta Bio ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Cabaletta Bio has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Cabaletta Bio a dividend aristocrat?
Cabaletta Bio is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Cabaletta Bio a dividend king?
Cabaletta Bio is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Cabaletta Bio a dividend stock?
No, Cabaletta Bio is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Cabaletta Bio stocks?
To buy Cabaletta Bio you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Cabaletta Bio stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.